After a tidal wave of lawsuits and months of heated debate about the regulatory status of the stimulant DMAA (1,3-Dimethylamylamine), USPLabs has agreed to settle a nationwide class action suit challenging the legality and safety of its top-selling DMAA...
The EU crackdown on health claims is unlikely to impact on US regulators, but it could provide ammunition to opportunistic plaintiffs’ attorneys this side of the Atlantic, experts have warned.
